A Sphingosine-1-Phosphate Receptor (s1pr) Modulator for Use in Treating a Patient Suffering from Alzheimer's Dementia

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the use of sphingosine-1-phosphate receptor (S1PR) modulators, such as fingolimod, for the treatment of Alzheimer's dementia. The invention is based on the surprising finding that S1PR modulators, which are already approved for treating multiple sclerosis, can halt or even reverse synaptic deficits and memory dysfunction in Alzheimer's disease—even at later disease stages. Furthermore, the patent claims that S1PR modulators can be used alone or in combination with other Alzheimer's-related drugs.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of patients diagnosed with Alzheimer's dementia to halt disease progression.
• Therapeutic intervention aimed at reversing cognitive and synaptic decline in late-stage Alzheimer's disease.
• Adjunct therapy in combination with other Alzheimer's medications (e.g., aducanumab, donepezil, memantine, antidepressants) for broader efficacy.
• Repurposing existing S1PR modulators (originally for multiple sclerosis) for use in neurodegenerative diseases.
• Development of new pharmaceutical compositions targeting neuroinflammation and synaptic dysfunction in Alzheimer's patients.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a potential disease-modifying therapy for Alzheimer's dementia, not just symptomatic relief.
• Ability to reverse established cognitive and synaptic deficits, even in late-stage disease.
• Utilizes drugs (like fingolimod) with established safety profiles for other indications, possibly accelerating regulatory approval and market introduction.
• Enables flexible treatment strategies, either as monotherapy or combination therapy with existing Alzheimer's drugs.
• Targets neuroinflammatory processes, addressing a key aspect of Alzheimer's pathology that is not handled by most current therapies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a sphingosine-1-phosphate receptor (S1PR) modulator for use in treating a patient suffering from Alzheimer's dementia.